Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Marky1on Jul 13, 2021 7:39pm
278 Views
Post# 33540271

RE::-)

RE::-)

YukonJezza wrote:
yes it was brilliant that the CEO sold 75000 shares in an already collapsing shareprice

 

Sorry for poking my head in here for a second...The REASON Dan sold shares at $4.00 is this!
Because of the amalgamation process he WAS stuck with a $300,000 tax bill..He had to pay taxes...that's it Mr. Yukon. nothing more, nothing less. Stop your senseless bashing of our CEO..not warranted at all.

Because  of Dan's leadership, and as Mr. Mugsy so wisely pointed out.

1) we have an amazing 70 million dollars in the bank...giving us a much stronger company, enough money to begin P3 testing on our own, if need be...Let's not forget the other 80M USD coming our way from Nuance..

2) Getting Don Haut on the partnership committee is all Dan's doing..I'd say that he's been in communication with Bayer and preparing a partnership/ buyout of 346 at this very moment!

3) Dan once told me that they will be progressing in a Joe Biden fashion...slowly, methodically and intelligently . I think this is a prudent way of proceeding...Don't you?

4) catalysts are plentiful and will be brought forward when Dan is ready to do so.. Remember, he has millions of shares of ATE, so he is perfectly aligned with us shareholders.

Catalysts include further partnership agreements, along the same lines of the Nuance deal, but larger deals for North America, Europe and China.   Bringing 352 and 340 into P1 clinical testing after a successful IND from the FDA. With more money in the bank, perhaps buying back some shares, similarly what GUD is doing. With consolidation our shares will be so much stronger in value.  Creating new molecules using Dr. Wallace's amazing H2S technology...thus expanding the patent life of our drugs.

Personally, for what it's worth.. I think that only otenaproxesol will be sold separately  not the entire company. Imagine 2B$ USD in our bank account! As Dan has said...pass the baton to someone else.
 In conclusion, please keep your negativity, Yukon and ABC to yourself....no sane person will agree with you..
 

<< Previous
Bullboard Posts
Next >>